After Hours
$
214.00
Change
+0.79 +0.37%
Volume
Volume 91,318
Nov 30, 2023, 7:58 p.m.
Quotes are delayed by 20 min
Previous close
$ 213.52
$ 213.21
Change
-0.31 -0.15%
Day low
Day high
$212.82
$213.95

52 week low
52 week high
$116.08
$217.51

Market cap
$40.28B
Average volume
1.40M
P/E ratio
N/A
Rev. per Employee
$706,496
EPS
-4.01
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on SGEN
-
Incyte Corp. stock rises Thursday, outperforms market
- MarketWatch Automation
-
ImmunoGen Stock Soars 81% on AbbVie's $10.1 Billion Takeover
- Barron's Online
-
Incyte Corp. stock rises Wednesday, outperforms market
- MarketWatch Automation
-
Incyte Corp. stock falls Tuesday, underperforms market
- MarketWatch Automation
-
Incyte Corp. stock falls Monday, underperforms market
- MarketWatch Automation
-
Incyte Corp. stock underperforms Friday when compared to competitors despite daily gains
- MarketWatch Automation
-
Incyte Corp. stock rises Wednesday, still underperforms market
- MarketWatch Automation
-
Incyte Corp. stock underperforms Tuesday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock falls Thursday, underperforms market
- MarketWatch Automation
-
Incyte Corp. stock rises Wednesday, outperforms market
- MarketWatch Automation
-
Incyte Corp. stock outperforms competitors on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock outperforms market on strong trading day
- MarketWatch Automation
-
Incyte Corp. stock underperforms Friday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock underperforms Thursday when compared to competitors
- MarketWatch Automation
-
Incyte Corp. stock falls Wednesday, underperforms market
- MarketWatch Automation
-
Pfizer's Weight Loss Pill Is a Do-Or-Die Milestone
- Barron's Online
-
Incyte Corp. stock rises Tuesday, still underperforms market
- MarketWatch Automation
-
Incyte Corp. stock falls Monday, underperforms market
- MarketWatch Automation
- Loading more headlines...
Analyst Ratings
-
Wall Street Is Bullish on Nektar Stock despite Stock Price Slump
- MarketRealist.com
-
Benzinga's Top Upgrades, Downgrades For October 20, 2017
- Benzinga.com
-
Shkreli: I'd Short Immunomedics On The Bounce
- Benzinga.com
Other News on SGEN
-
AbbVie to Buy ImmunoGen for More Than $10 Billion
- The Wall Street Journal Interactive Edition
-
How Biden’s Inflation Reduction Act Killed a Cancer Study
- The Wall Street Journal Interactive Edition
-
‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weapon
- The Wall Street Journal Interactive Edition
-
Pfizer Looks for a Covid Bottom
- The Wall Street Journal Interactive Edition
-
The Hedge Fund That Made a Killing Betting Against Lina Khan
- The Wall Street Journal Interactive Edition
-
S&P 500 Drops for Third Straight Week
- The Wall Street Journal Interactive Edition
-
Biden FTC’s Antitrust Bark Proves Worse Than Its Bite
- The Wall Street Journal Interactive Edition
-
Pfizer’s Covid Boost Crashes to Earth
- The Wall Street Journal Interactive Edition
-
Deal Activity Slumps as Pricing Proves to Be a Sticking Point
- The Wall Street Journal Interactive Edition
-
FTC’s Amgen Activism Will Spare Smaller Biotechs
- The Wall Street Journal Interactive Edition
-
Pfizer’s Earnings Fall With Cooling Demand for Covid-19 Products
- The Wall Street Journal Interactive Edition
-
Starbucks, Ford, Apple Lead Another Busy Earnings Week
- The Wall Street Journal Interactive Edition
-
- Edgar Online - (EDG = 10Q, 10K)
-
Bristol-Myers CEO Giovanni Caforio to Step Down
- The Wall Street Journal Interactive Edition
-
How to Tell Biotech’s Likely Winners From Losers
- The Wall Street Journal Interactive Edition
-
Merck to Buy Prometheus Biosciences
- The Wall Street Journal Interactive Edition
-
First Republic Bank, T-Mobile, Credit Suisse: Stocks That Defined the Week
- The Wall Street Journal Interactive Edition
-
- The Wall Street Journal Interactive Edition
-
Pfizer Agrees to Buy Seagen for $43 Billion
- The Wall Street Journal Interactive Edition
-
Pfizer Overpays for Seagen, but Who’s Counting
- The Wall Street Journal Interactive Edition
- Loading more headlines...
Press Releases on SGEN
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, SPPI, HOTH
- PR Newswire - PRF
-
Seagen Reports First Quarter 2023 Financial Results
- BusinessWire - BZX
-
MindMed Files Preliminary Proxy Statement for 2023 Annual Meeting
- BusinessWire - BZX
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates SGEN, UNVR, CVT
- PR Newswire - PRF
-
Seagen to Report First Quarter 2023 Financial Results on April 27, 2023
- BusinessWire - BZX
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TA, SGEN, UNVR, USX
- PR Newswire - PRF
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com